Omidenepag isopropyl - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for omidenepag isopropyl and what is the scope of freedom to operate?
Omidenepag isopropyl
is the generic ingredient in one branded drug marketed by Visiox Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.Omidenepag isopropyl has one hundred and twenty-nine patent family members in thirty-two countries.
One supplier is listed for this compound.
Summary for omidenepag isopropyl
| International Patents: | 129 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Clinical Trials: | 1 |
| Patent Applications: | 44 |
| What excipients (inactive ingredients) are in omidenepag isopropyl? | omidenepag isopropyl excipients list |
| DailyMed Link: | omidenepag isopropyl at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for omidenepag isopropyl
Generic Entry Date for omidenepag isopropyl*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for omidenepag isopropyl
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Santen Pharmaceutical Asia Pte. Ltd. | Phase 4 |
Pharmacology for omidenepag isopropyl
| Drug Class | Prostaglandin E2 Receptor Agonist |
| Mechanism of Action | Prostaglandin E2 Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for omidenepag isopropyl
US Patents and Regulatory Information for omidenepag isopropyl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visiox Pharma | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Visiox Pharma | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Visiox Pharma | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Visiox Pharma | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Visiox Pharma | OMLONTI | omidenepag isopropyl | SOLUTION;OPHTHALMIC | 215092-001 | Sep 22, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for omidenepag isopropyl
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2019131901 | ⤷ Subscribe | |
| South Korea | 102281620 | ⤷ Subscribe | |
| Canada | 2757291 | COMPOSITION PHARMACEUTIQUE POUR LA PREVENTION OU LE TRAITEMENT DU GLAUCOME (PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA) | ⤷ Subscribe |
| Portugal | 2415763 | ⤷ Subscribe | |
| Denmark | 2415763 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
